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Objective To improve HIV treatment in China by determining changes over
time of patient characteristics (geographic, clinical and route of HIV
infection) among patients enrolled in the China National Free
Antiretroviral Treatment Program.
Methods Patients in the national treatment database from 1 June 2002 to 1
June 2009 were eligible. Patients were excluded if <18 years old,
not previously treatment-naı ¨ve, missing initial treatment date or
not initiated on triple drug therapy.
Results About 62919 patients were included, located across 54.8% of coun-
ties/districts throughout mainland China; 86.4% were concentrated
in 11.1% of counties/districts. Median age was 38 years, 41%
female, 45.4% former plasma donors (FPDs), 33.9% sexually in-
fected and 15.5% injection drug users (IDUs). Median baseline
CD4 cell count was 129/ml. In 2002, 100% of treated were FPDs
with no CD4 cell counts. By 2009, 59% of the treated were sexually
infected and 96% had baseline CD4 cell counts. Injection drug users
remained a minority of those treated.
Conclusions Limited treatment resources can be focused on areas with more
patients. Greater emphasis needs to be placed on earlier HIV diag-
nosis and treatment. New strategies must be identified to bring
HIV-infected IDUs into treatment. Routine HIV testing would iden-
tify those at risk earlier.
Keywords China, HIV, national treatment program, baseline characteristics,
injection drug users, routine testing
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ii56Introduction
The HIV epidemic in China has been concentrated
primarily in the high-risk cohorts of former plasma
donors (FPDs), injection drug users (IDUs), female
sex workers (FSWs), and men who have sex with
men (MSM).
1–3 The FPDs were estimated to have
been infected predominantly in the early- to mid-
1990s and thus developed AIDS in large numbers by
the early 2000s. In response, the China Ministry of
Health created the Division of Treatment and Care
within the National Centre for AIDS/STD Control
and Prevention (NCAIDS) of the Chinese Centre for
Disease Control and Prevention (China CDC) in 2001
with the mandate to establish a national HIV treat-
ment program.
4–6
The China National Free Antiretroviral Treatment
Program (NFATP), which began in 2002, has ex-
panded each year since and has now treated over
80000 patients across the entire country.
7,8 Over
these past 8 years, the program has changed as dif-
ferent resources have become available. For instance,
drugs initially available through the NFATP included
Chinese-produced generic zidovudine, stavudine,
didanosine, nevirapine and indinavir. Branded lami-
vudine and efavirenz drugs became more widely
available from 2005 onwards. The objectives of this
article are to document the dramatic changes over
time of patient characteristics (geographic, clinical
and route of HIV infection) among patients enrolled
in the NFATP, and to highlight implications for im-
proving the quality of HIV care and treatment in
China.
Methods
Patients who met the national treatment guidelines of
CD4 cell count <200/ml, total lymphocyte count
<1200/ml, or the World Health Organization (WHO)
stage III/IV disease were initiated on highly active
antiretroviral therapy (HAART).
9 All patients treated
through the NFATP were prospectively captured in a
previously described
10 ongoing observational database
maintained at the NCAIDS. Baseline data captured
included patient demographics, self-reported route of
HIV infection, laboratory results including CD4 cell
count and viral load when available and initial treat-
ment regimen. Because of the difficulty in making
definitive diagnoses of opportunistic infections in
rural settings, easily diagnosed signs and symptoms
were used as a proxy (syndromic surveillance). The
categories were as follows: (i) fever; (ii) pulmonary
(cough, dyspnoea, chest pain, night sweats or lymph-
adenopathy); (iii) gastrointestinal (nausea, vomiting
or diarrhoea); (iv) skin or mucosal (rash, thrush or
oral hairy leukoplakia); and (v) central nervous
system (headache or visual changes). This informa-
tion was collected as part of a general review of sys-
tems and physical examination during the baseline
patient visit. Because Henan Province did not partici-
pate in the national treatment database until 1 July
2006, baseline CD4 cell counts for Henan patients
before then were collected instead from the national
HIV epidemiology database, also maintained by the
NCAIDS.
All patients enrolled in the database from 1 June
2002 to 1 June 2009 were eligible for this analysis.
Patients were excluded if they were <18 years old,
were not previously treatment naı ¨ve, were not initially
treated through the NFATP, had a missing initial
treatment date or were not initiated on triple drug
therapy. Overall baseline characteristics between
routes of infection were compared with ¼0.05,
using the Pearson 
2 test for categorical variables
and the non-parametric Kruskal–Wallis test for con-
tinuous variables because none fulfilled the
Kolmogorov–Smirnov test for normality. Pairwise
comparisons between routes of infection used
Pearson 
2 for categorical variables and the Mann–
Whitney test for continuous variables when the over-
all test is significant, using a Bonferroni adjusted
¼0.0083 (0.05/6). Baseline characteristics by time
were compared using the Pearson 
2 test, with time
categorized as 2002–04, 2005–06 and 2007–09. All
hypotheses testing were two-sided. Data were ana-
lyzed using SPSS version 17.0 (SPSS Inc., Chicago,
IL, USA). To present a geographical distribution of
the routes of infection, a map was generated using
MapInfo Professional, version 6.5 (Pitney Bowes
Software Inc., Troy, NY, USA) using county and dis-
trict level data. Each dot represented 20 patients and
each county or district with at least 20 patients was
stratified by colour into route of transmission, based
on whichever route(s) represented 450% of transmis-
sions in that area. Some provinces did not have one
route comprising 450% of transmissions but had
sexual and IDU transmissions together comprising
450% of transmissions and were classified as
sex-IDU mixed. Data analyses were approved by the
institutional review board of the NCAIDS.
Results
As of 1 June 2009, a cumulative total of 66694 pa-
tients had begun HAART through the NFATP. After
excluding patients previously treated (N¼1802), age
<18 years or unknown (N¼1335), who started on
only one or two drugs (N¼1134, most likely due to
data transcription errors) or with missing treatment
initiation date (N¼496, above categories not mutual-
ly exclusive), 62919 (94.3%) patients were included in
this analysis. Among all treated patients, 45.4% were
FPDs, 15.5% IDUs and 33.9% sexually infected
(Table 1), among whom 1245 (5.8%) were reported
as MSM. At baseline, median age was 38 years and
41% were female, with FPDs being older and IDUs
predominantly male. Overall, 74.2% had a baseline
CD4 cell count, comprising only 50.1% of FPDs but
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ii58 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY96.5% of IDUs and 93.4% of those infected sexually.
Those infected sexually had a significantly lower
median CD4 cell count and a significantly higher pro-
portion with CD4 cell counts <50/ml than patients
with other routes of transmission. However, if the
other 50% of FPDs who were predominantly treated
in the earlier years had also had CD4 cell counts done,
their overall median CD4 cell count would likely be
lower because significantly more FPDs had more
baseline sign/symptom categories consistent with
severe immunosuppression. Only 5% had a baseline
viral load performed. Among the 86.3% with baseline
liver function tests, IDUs had significantly more ab-
normal tests and proportion with alanine
aminotransferase480U/l. Of note, the majority of
variables between the sexually transmitted cohort
and the unknown transmission cohort were not stat-
istically different, suggesting that the majority of
those with unknown HIV transmission routes may
have acquired their infection sexually.
Among a total of 2950 counties and districts across
mainland China, the 62919 treated patients were
located in 1617 (54.8%) counties/districts, showing
the broad spread of HIV across mainland China. Of
these, only 327 counties/districts, encompassing
54338 (86.4%) patients, had at least 20 patients,
demonstrating that the vast majority of patients
were concentrated in only 11.1% of the counties/dis-
tricts. These 327 counties/districts and patients were
mapped and stratified by route of transmission
(Figure 1). The largest concentration of treated pa-
tients was FPDs located in and around Henan
Province. Southern China, particularly Yunnan,
Guangxi and Guangdong Provinces, had a mixture
of sexual and IDU transmissions. Xinjiang Province,
to the West, was predominantly IDU-driven, with
some sexual transmissions reported as well. Overall,
when stratifying the 327 counties by primary route(s)
of transmission, transmission by blood encompassed
134 (41%) of counties; by sex, 105 (32%); by IDU, 71
(22%) and by sex-IDU mixed, 17 (5%).
The baseline characteristics of those treated changed
significantly over time (Figure 2). Although almost
100% of those initiating treatment in 2002–03 were
Figure 1 Among 62919 patients included in this analysis, the 54338 (86.4%) of patients located in the 327 counties/districts
with at least 20 patients each were plotted on this map, with each county/district stratified by predominant mode of HIV
transmission
ANTIRETROVIRAL THERAPY IN CHINA ii59FPDs, this changed to 14% infected by blood, 59%
sexually infected and 21% IDUs during the first half
of 2009. No baseline CD4 cell counts were done
when the NFATP first began but, by 2009, 96% had
a baseline CD4 cell count. Of these, the proportion
entering care with known CD4 cell count <50/ml
has remained relatively constant since 2006 at
 25%. In 2002–03, the predominant first-line anti-
retroviral drugs available were zidovudine, stavudine,
didanosine and nevirapine, with a very small amount
of lamivudine and efavirenz. Consequently, almost
everyone received a didanosine-based regimen.
Lamivudine became widely available in 2005 and,
since then, has essentially replaced didanosine.
During the first half of 2009, 74% of patients initiated
treatment with zidovudine/stavudineþlamivudineþ
nevirapine. Zidovudine and stavudine usage rates
(49 and 51%, respectively) have been about equal
over time, with stavudine having been used more
before 2007 and zidovudine used predominantly start-
ing in 2007. Efavirenz has been used as initial therapy
primarily for those diagnosed with HIV–tuberculosis
co-infection. The changes in all four baseline
comparisons (new patients, route of infection, CD4
cell count and initial treatment regimen) over time
were statistically significant (P<0.0001).
Discussion
Our analysis of the baseline characteristics of patients
entering the China NFATP between 2002–09 reflects a
developing country’s programme in transition as it
scaled up to meet the needs of the patient population.
Overall, the 62919 patients included in this analysis
at baseline were predominantly young, majority male
and predominantly infected via plasma donation.
These patients were spread across 55% of all coun-
ties/districts across mainland China but 86% were
concentrated in only 11% of all counties/districts.
When these demographics were stratified by year,
however, a number of stark changes were noted in
the baseline characteristics of patients entering the
NFATP. The predominant route of transmission
shifted from 100% FPDs in 2002 to 59% sexual,
21% IDU and only 14% by blood in 2009. Baseline
Figure 2 Baseline characteristics among all 62919 patients included in this analysis, stratified over time by the number of
new patients initiating highly active antiretroviral therapy (HAART), route of transmission, baseline CD4 cell count and
treatment regimen. The number of new patients included by year is shown in the top graph.
Note: 2009 data are only to June 1 2009. P<0.0001 for the change in each comparison (number of new patients, route of
infection, baseline CD4 cell count and initial HAART regimen) over time
ii60 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYCD4 cell count testing increased from none to 96%,
with overall median CD4 cell count of 129/ml. The
treatment regimens used transitioned from a
didanosine-based to a lamivudine-based regimen. As
we consider the ramifications of these changes, clear
public health implications emerge, which can be used
to guide and improve HIV treatment practices in
mainland China and in other developing countries’
HIV treatment programmes.
One of the most striking changes is the increase in
numbers and geographic distribution of treated pa-
tients over 7 years, from 40 patients in one county
in 2002 to 62919 in 55% of all counties/districts
across mainland China in 2009. Scaling up the
NFATP to cover such a vast area over a relatively
short amount of time was no small feat.
11 From 2002
to 2005, treatment was more of an emergency response
to the medical needs among FPDs. A training curricu-
lum was designed for all levels of clinicians, from in-
fectious diseases specialists to village doctors,
4 with a
national training manual developed to provide uni-
form teaching.
9 Data from all treated patients were
collected on standardized forms and maintained cen-
trally in an observational database to facilitate research
and analysis.
10 After 2005, treatment became more
standardized and was broadened to other cohorts.
Starting in 2008, the national HIV treatment guide-
lines were revised to initiate treatment among patients
with CD4 cell count from <200/ml. Analyses of treat-
ment outcomes to date have shown the success of the
NFATP, with dramatically reduced mortality rates
among treated patients, from 22.6/100 person-years
at treatment initiation to 4–5/100 person-years after
6 months, sustained across 5 years.
8,12
Two other profound baseline changes in the NFATP
are the shift in route of transmission of treated pa-
tients and availability of CD4 cell counts over time.
When the programme began in 2002–03, the extent of
the FPD epidemic was just beginning to be under-
stood and treatment was initiated in this cohort
first. At that time, the treatment infrastructure and
laboratory capacity were limited, particularly in the
rural areas where the FPDs were located. Treatment
was begun predominantly based on reported symp-
toms and total lymphocyte count. As the programme
matured and the NFATP expanded nationwide, the
primary route of transmission for those initiating
treatment shifted away from FPDs and more towards
sexual transmission, consistent with national epi-
demiology data.
13 CD4 cell count capacity expanded
such that, in the first half of 2009, 96% of patients
initiated treatment based on a pre-treatment CD4
cell count. The CD4 cell count results, however, indi-
cated an important area of clinical and public
health improvement––initiating HAART before
patients become too immunosuppressed. Median
baseline CD4 cell count among all patients was only
129/ml, with 28% having a CD4 cell count <50ml.
Among those infected sexually, median CD4 cell
count was only 112/ml. We and others have shown
that initiating treatment at low CD4 cell counts has
worse long-term outcomes than initiating treatment
earlier;
8,14–17 thus, this combination of increasing
numbers of patients infected sexually but with low
presenting CD4 cell counts is of great concern. The
change in national treatment criteria from CD4 cell
count of 200–350/ml will be of little benefit if patients
continue to present so with such low CD4 counts.
Additional outreach is needed among the high-HIV-
risk cohorts in China to encourage increased testing
and to educate them regarding the benefits of earlier
treatment, with free treatment offered to those eli-
gible. This is particularly important because the ma-
jority of those initiating treatment in recent years are
IDUs and those infected sexually, including FSWs and
MSM. These populations are marginalized and stig-
matized in China and may not come in for care until
they are extremely ill. China previously made HIV test-
ing routine among FPDs, which caused some contro-
versy.
18 Yet, the subsequent survival benefit to those
identified and treated is now documented.
7,8 Routine
HIV testing is also offered among other high-risk
groups in China
19 but, despite this, most patients con-
tinue to initiate treatment at very immunosuppressed
levels, suggesting routine testing alone has been insuf-
ficient in identifying patients earlier. Consideration
should be given to making HIV testing routine to the
general public in areas with a known high prevalence
of HIV infection, similar to what has been successfully
done elsewhere.
20,21
Injection drug use has been one of the primary
routes of HIV infection in China, with the first re-
ported HIV outbreak in China among IDUs in 1989.
2
In prevalence estimates of HIV in China, injecting
drugs was always the primary route of transmission
until 2007 when IDUs, accounting for 38% of reported
routes of transmission, were second only to those
infected via heterosexual transmission, at 41%.
13 Yet,
despite IDUs being likely the earliest infected cohort
and comprising the largest infected cohort in China
until the 2007 estimate, only a cumulative total of
15.5% of treated patients were IDUs. The reasons for
this are likely multifactorial, including social–political
(stigma, incarceration), individual (fear of side ef-
fects, low HAART self-efficacy, addiction-related in-
stability) and provider-based (physician perception,
inexperience) reasons.
22 More research needs to be
done to explore strategies to increase access to treat-
ment in this population in China, such as possibly
combining and expanding antiretroviral treatment
and methadone maintenance treatment clinics.
19
Among all patients in our analysis, the IDUs stood
out as having significantly more abnormal liver func-
tion test results. Co-infection of HIV with hepatitis C
virus (HCV) is a well-known complication with this
cohort,
23–26 and a number of studies have demon-
strated high rates of co-infection with HIV, hepatitis
B virus (HBV) and HCV.
27–30 Among the FPDs,
ANTIRETROVIRAL THERAPY IN CHINA ii61studies have shown high rates of HCV co-infection
31–
33 but relatively low rates of HBV infection,
34,35
despite the endemicity of HBV in China, because
HBV-positive plasma donors were screened out
before donation. This has implications for the
long-term treatment of HIV and hepatitis in China.
Hepatitis screening, unfortunately, has not been
done systematically within the NFATP but will be
incorporated into standard baseline testing at treat-
ment initiation in the future. Hepatic adverse effects
of antiretroviral therapy need to be monitored, par-
ticularly among the IDUs. With mortality now signifi-
cantly reduced among treated HIV patients in
China,
7,8 plans for treating HIV/hepatitis co-infections
need to be considered. Tenofovir and lamivudine will
be introduced as first-line treatment for those
co-infected with hepatitis B. How to treat patients
co-infected with hepatitis C is a significant challenge
because the treatments are expensive, complex and
have significant side effects.
There are limitations associated with this analysis.
First, the data come from an observational database
and therefore may have inherent biases, such as re-
porting or recall biases, associated with the collection
of non-random data. However, the large number of
patient observations in the database should help miti-
gate any single bias in any one direction. Secondly,
route of infection is self-reported and not always
straightforward to ascertain. Although the FPDs as a
cohort may have few additional HIV risk factors,
sexual transmission and IDU cohorts often overlap.
36
Sex workers may inject drugs and IDUs may sell sex
to purchase drugs. Despite this overlap, baseline dif-
ferences between these two cohorts in our data sug-
gest that this overlap was not that great. Some of
these differences were clinically meaningful, such as
higher abnormal liver function test results with the
concern about higher rates of viral hepatitis
co-infection in IDUs, while others were not, such as
the need to promote earlier HIV testing and treatment
among all cohorts.
As the NFATP moves forward, lessons and trends
from the initial 7 years can guide the program to al-
locate more effectively the limited resources available.
Although HIV infections are spread across more than
half of China, 86% of treated patients are concen-
trated in only 11% of counties/districts; thus, the
bulk of resources will need to focus on these areas.
Creative strategies must be developed to identify and
treat earlier those infected sexually and through in-
jecting drugs, with consideration given to encourage
routine HIV testing for all who live in high-prevalence
areas. CD4 cell counts have already been scaled up
and viral load testing and hepatitis screening are scal-
ing up now. Although these lessons are specific to
China, the principles on which they are based are
applicable to other developing countries with limited
resources. Monitoring and evaluation of treatment
outcomes is critically important to understanding
the effectiveness of treatment programmes and
usage rates and trends for planning purposes. For ex-
ample, national programmes may not need to target
the entire country. Geographic locations and risk co-
horts that were hot spots several years ago may not be
so today. Programmes must be flexible enough to
adapt to changing trends and needs. This would not
be possible without standardized data collection pro-
cedures put in place on a national or other large-scale
database. Analyses should be performed routinely to
ensure that limited resources are allocated effectively
and that the cohorts most in need of treatment are
reached. China’s NFATP has improved through care-
ful analyses of its data and will continue to adapt in
response to new data trends and scientific results.
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KEY MESSAGES
  The vast majority of patients are concentrated in a few areas and limited treatment resources can be
focused in these areas.
  Patients still present very late in their disease course and greater emphasis needs to be placed on
earlier HIV diagnosis and treatment.
  Injecting drug users (IDU) comprise a disproportionately low percent of those treated, compared to
the overall national epidemiology. New strategies must be identified to bring HIV-infected IDUs into
treatment.
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